ReviewFrontiers in psychiatry2026
AI-enabled passive digital phenotyping of experiential negative symptoms in schizophrenia-spectrum disorders: a narrative review on the path from sensing to clinical endpoints.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms, particularly avolition and asociality, rank among the most disabling and treatment-resistant features of schizophrenia-spectrum disorders. Clinician-rated scales such as the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale have strengthened construct definition. However, they depend on infrequent interviews and retrospective recall, missing the moment-to-moment behavioral patterns that define these symptoms in everyday life. Passive digital phenotyping, through smartphones and wearable sensors, can continuously capture mobility, physical activity, sleep, social rhythms, and speech acoustics under real-world conditions. Whether artificial intelligence can convert these noisy, incomplete, and context-dependent data streams into clinically valid digital endpoints remains the central unresolved question. This narrative review synthesizes evidence on AI-enabled passive digital phenotyping of experiential negative symptoms in schizophrenia-spectrum disorders. We propose a construct-to-endpoint pipeline that links construct definition, multimodal representation learning, and fit-for-purpose clinical validation to interpretable digital markers and just-in-time adaptive interventions. Current evidence reveals consistent but modest associations between passive sensing modalities and negative symptoms. However, single-modality correlations do not constitute valid endpoints. A qualified digital endpoint must demonstrate analytical validity, clinical validity, longitudinal sensitivity, external transportability, and patient meaningfulness. Key challenges span data-level issues such as resolution mismatch and device heterogeneity, inferential risks including environmental confounding and algorithmic bias, and ethical-regulatory concerns involving privacy and model opacity. The field should now prioritize construct-anchored, context-aware, and interpretable digital endpoints that can serve as outcome measures in negative-symptom trials and support personalized longitudinal monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.